Clinical Trial Update: Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intermittent versus continuous venetoclax in combination with acalabrutinib for chronic lymphocytic leukemia and small lymphocytic lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Venclexta (venetoclax)

Snippet

Sponsor: Zulfa Omer | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING